WAYS TO IMPROVE THE SYSTEM OF PHARMACOTHERAPY OF THYROID DISEASES IN UKRAINE

Yuliia Vadziuk*

Department of Clinical Laboratory Diagnostics, Ternopil State Medical University, Ternopil, Ukraine.

ABSTRACT

Recent years thyroid diseases are attracting considerable attention. On one hand, this is due to the fact that thyroid is actively reacts on environment, followed by appearance of various diseases. On the other hand, in current conditions population remains face to face with adverse impact of environment because an effective experience of the world community to fight against iodine deficiency is not implemented in Ukraine. Thus every year becomes more patients with thyroid pathology. So there becomes a need to optimize the system of healthcare provision for these patients. Therefore, the aim of our research was to analyze list of drugs for treatment of thyroid diseases, listed in Ukrainian National Formulary in accordance with international standards (British National Formulary and WHO Model List of Essential Medicines).

KEYWORDS: marketing analysis, pharmacotherapy, thyroid diseases.

INTRODUCTION

Nowadays significant attention of world's scientists is paid to effectiveness and safety of medicines and optimizing healthcare needs.\(^1\) The implementation of social medical insurance in Ukraine, which the Ministry of Health plans to introduce till the end of 2016 will facilitate this.\(^2\) The main tool to ensure proper prescribing and use of drugs is formulary system.

Formulary system is based on criteria of evidence; it provides cost efficiency, rational prescribing and use of drugs according to established standards. The process of
Implementation of formulary system can be seen as the optimization of drug therapy in rationalization process of drugs selection in order to increase therapeutic benefits depending on cost of their purchase.\textsuperscript{[3]}

It is known that the thyroid disorders are very common, affecting 750 million people worldwide by recent World Health Organization (WHO) estimates, being possibly even more prevalent than diabetes.\textsuperscript{[4]} Analysis of official statistical data the Ministry of Health of Ukraine (2009) found a high prevalence of endocrine diseases in Ukraine. According to these criteria endocrine pathology takes one of leading places in the structure of general morbidity. There are a growing number of patients with different endocrinopathies in Ukraine, but the most common among them - thyroid disease (47\% of all diseases of endocrine system).\textsuperscript{[5]} So we have identified the need for analysis of drugs for treatment of thyroid disease included to the Ukrainian National Formulary (UNF) according to international guidelines.

**MATERIALS AND METHODS**

We have analyzed medications listed in UNF and studied the dynamics of its formation (2010-2014 years). A comparative analysis of UNF with the British National Formulary (BNF) was conducted. The compliance of UNF with the WHO Model List of Essential Medicines was checked.

**RESULTS**

As of January 2015 in Ukraine come out six editions of UNF containing recommendations for prescribing and rational use of drugs considering efficiency, safety and economic feasibility.

We made comparative analysis of assortment dynamic of Formulary medications for treatment and prevention of thyroid disease that were included to the 2nd, 4th and 6th editions of UNF (Figure 1).
As we can see from figure 1, the number of medications of test group included to different editions of UNF is not significantly different. To the fourth edition of UNF 4 new foreign drugs (India, Serbia) were added and 2 domestic drugs were excluded. At inclusion of medications to 6th edition of UNF there was rotation of three foreign drugs. Inclusion and exclusion of trade names may be associated with expiry of registration certificate or registration of new drugs, because only those drugs that have active registration certificate at the time of viewing are included to Formulary.

WHO considers that 80-90% of health care needs can provide 700-800 items of drugs. Therefore, the use of high-quality and safe medicines will help reduce morbidity and mortality in many countries. WHO Model List of Essential Medicines has recommendation function and is used as a basis for drafting relevant national lists.[6]

We have analyzed presence of medicines for treatment of thyroid diseases included to Ukrainian National Formulary (6th edition) according WHO Model List of Essential Medicines (18th Edition) (Table 1).

Table 1: The presence of drugs for treatment of thyroid diseases in UNF according to WHO Model List of Essential Medicines.

<table>
<thead>
<tr>
<th>WHO Model List of Essential Medicines</th>
<th>WHO recommended drug and dosage form</th>
<th>Presence of drugs in UNF</th>
<th>Presence of WHO recommended drug form</th>
<th>Presence of WHO recommended dosage form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levothyroxine</td>
<td>Tablet: 25 micrograms, 50 micrograms, 100 micrograms</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Potassium iodide</td>
<td>Tablet: 60 mg</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td>Tablet: 50 mg</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
As can be seen from table 1, among drugs for treatment of thyroid disease which are present in UNF only medications of levothyroxine are available in recommended drug form and dosage. Completely absent medications of propylthiouracil and potassium iodide drugs have no appropriate dosage form. On the next stage we analyzed and compared British National Formulary (68th edition) and Ukrainian National Formulary (6th edition).

In UNF drugs for treatment of thyroid diseases are included to Chapter 7 "Endocrinology. Drugs", section 3 "Medicines for treatment of thyroid disease", which contains three subsections: 1. Thyroid hormones, 2. Antithyroid drugs, 3. Iodine drugs.

Analyzing the BNF we paid attention to the fact that drugs included here only by the original names, unlike UNF, which include both original and generic drugs. Prices of drugs in BNF indicated for full medication package, in UNF the price is calculated by defined daily dose. Drugs for treatment of thyroid diseases are included to Chapter 6 (Endocrinology), section 2 (thyroid and antithyroid drugs), subsections 1. Thyroid hormones, 2. Antithyroid drugs.

According to recommendations of BNF, thyroid hormones include levothyroxine sodium and liothyronine sodium (absent in UNF).

Antithyroid drugs of BNF contain carbimazole, propylthiouracil and iodine. Very important are recommendations for elimination thyrotoxic crisis, which added to this subsection. Also, the description of use of carbimazole drugs contain warning for doctors regarding caution of use of these medicines because of possibility of side effects (neutropenia, agranulocytosis), and provided detailed action plan for prevention of negative consequences.

**DISCUSSION**

Results of comparative analysis of assortment dynamic of Formulary medications for treatment and prevention of thyroid disease that were included to the 2nd, 4th and 6th editions of UNF showed that foreign drugs had an advantage of inclusion to formulary. There is a need to provide arguments concerning evidence of clinical and cost effectiveness of drugs included in UNF, indicating the level of evidence (this is consistent with research results of Panfilova 2009).[7]

The main difference between British National Formulary and Ukrainian National Formulary is that drugs are brought in BNF only by original name that allows updating formulary twice a year. This approach has sustainable rational foundation, because the certificate of drugs
registration have time limits, which means that current principle of formulation of UNF requires constant monitoring of drugs registration and updating on daily basis. Taking into account principle of BNF regulations, validity of medicines registration and inability to update formulary on a constant basis, we consider it necessary to offer optimization of domestic formulary manual in accordance with international practices and to include drugs in Ukrainian National Formulary exclusively by original name.

In UNF antithyroid drugs are presented by thiamazole that is absent in WHO Model List of Essential Medicines and BNF. We consider it necessary to include carbimazole in this group of drugs because its use is accompanied by decrease of side effects and allergic reactions and it will allow patients to continue treatment of diffuse toxic goiter and achieve clinical and immunologic remission. Therapeutic effects of carbimazole and thiamazole are equivalent.\(^8\)

We recommend inclusion of propylthiouracil to UNF because it's included to the World Health Organization Model List of Essential Medicines. It is used only in pregnant women in first trimester and in case of thiamazole intolerance in patients who refuse other treatments.\(^9\)

We also suggest unification of subsections 7. 3. 2 and 7. 3. 3 of Ukrainian National Formulary to one general subsection "antithyroid drugs" according to British National Formulary and considering presence of only one position (potassium iodide) in subsection 7. 3. 3.

**CONCLUSIONS**

Based on research results, we recommend:

1. To provide arguments concerning evidence of clinical and cost effectiveness of drugs included to UNF, indicating the level of evidence.
2. To include drugs in Ukrainian National Formulary exclusively by original name.
3. To include carbimazole medications into group of antithyroid drugs in UNF.
4. To include propylthiouracil medications into group of antithyroid drugs in UNF.
5. To unite subsections 7. 3. 2 and 7. 3. 3 of UNF to one general subsection "antithyroid drugs".

**REFERENCES**


